# EDGAR Filing Document

**Accession Number:** 0001662774
**File Stem:** 0001193125-26-161725
**Filing Date:** 2026-4
**Character Count:** 21128
**Document Hash:** 5cf2708f9d09039bf5535898ba936e84
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-161725.hdr.sgml**: 20260417

**ACCESSION NUMBER**: 0001193125-26-161725

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 13

**FILED AS OF DATE**: 20260417

**DATE AS OF CHANGE**: 20260417

**EFFECTIVENESS DATE**: 20260417

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Quince Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001662774
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 901024039
- **STATE OF INCORPORATION:** CA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-295164
- **FILM NUMBER:** 26872365

**BUSINESS ADDRESS:**
- **STREET 1:** 611 GATEWAY BLVD., SUITE 273
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 415-910-5717

**MAIL ADDRESS:**
- **STREET 1:** 611 GATEWAY BLVD., SUITE 273
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cortexyme, Inc.
- **DATE OF NAME CHANGE:** 20160104

**As filed with the Securities and Exchange Commission on April 17, 2026** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8**

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## Quince Therapeutics, Inc.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **90-1024039** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**611 Gateway Boulevard, Suite 273** 

**South San Francisco, CA 94080** 

**(415) 910-5717**

**(Address of Principal Executive Offices) (Zip Code)** 

**Quince Therapeutics, Inc. 2019 Equity Incentive Plan** 

**Quince Therapeutics, Inc. 2019 Employee Stock Purchase Plan** 

**(Full title of the plan)** 

**Dirk Thye** 

**Chief Executive Officer** 

**Quince Therapeutics, Inc.** 

**611 Gateway Boulevard, Suite 273** 

**South San Francisco, CA 94080** 

**(Name and address of agent for service)** 

**(415) 910-5717** 

**(Telephone number, including area code, of agent for service)** 

***Please send copies of all communications to:*** ****

**David F. Marx** 

**Dan Lyman**

**Dorsey & Whitney LLP** 

**111 S. Main Street, Suite 2100** 

**Salt Lake City, Utah 84111** 

**(801) 933-7360** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**REGISTRATION OF ADDITIONAL SHARES** 

**PURSUANT TO GENERAL INSTRUCTION E** 

Pursuant to General Instruction E of Form S-8, Quince Therapeutics, Inc. (the "Registrant") is filing this registration statement on Form S-8 (the "Registration Statement") with the Securities and Exchange Commission (the "Commission") to register the offering of an additional 268,293 shares of common stock (the "Registered Shares"), par value $0.001 per share ("Common Stock") of the Registrant, giving effect to the 1-for-10 reverse split of the Registrant's shares of common stock effected as of April 10, 2026 (the "Reverse Split"). The Registered Shares being registered herein include (i) 214,635 shares of Common Stock, issuable pursuant to the Registrant's 2019 Equity Incentive Plan (the "2019 EIP"), giving effect to the Reverse Split and (ii) 53,658 shares of Common Stock issuable pursuant to the Registrant's 2019 Equity Stock Purchase Plan (the "2019 ESPP"), giving effect to the Reverse Split. These additional shares of Common Stock are securities of the same class as other securities for which previous registration statements on Form S-8 were filed with the Commission on [<u>May</u> <u>9, 2019</u>](http://www.sec.gov/Archives/edgar/data/1662774/000119312519142424/d731096ds8.htm) (File No. 333-231307), [<u>March</u> <u>16, 2020</u>](http://www.sec.gov/Archives/edgar/data/1662774/000119312520074898/d869414ds8.htm) (File No. 333-237199), [<u>March</u> <u>1, 2021</u>](http://www.sec.gov/Archives/edgar/data/1662774/000119312521063853/d131962ds8.htm) (File No. 333-253743), [<u>March</u> <u>1, 2022</u>](http://www.sec.gov/Archives/edgar/data/1662774/000119312522061705/d179516ds8.htm) (File No. 333-263186), [<u>March</u> <u>15, 2023</u>](http://www.sec.gov/Archives/edgar/data/1662774/000119312523071454/d477001ds8.htm) (File No. 333-270577), [<u>April</u> <u>1, 2024</u>](http://www.sec.gov/Archives/edgar/data/1662774/000119312524083605/d816522ds8.htm) (File No. 333-278440), and [March 24, 2025](http://www.sec.gov/Archives/edgar/data/1662774/000119312525061463/d837482ds8.htm) (File No. 333-286063) (collectively, the "Prior Registration Statements"). Accordingly, the contents of the Prior Registration Statements are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8. The Registered Shares which represent shares of Common Stock have become reserved for issuance as a result of the operation of the "evergreen" provisions in each of the 2019 EIP and 2019 ESPP, which provide that the total number of shares subject to such plan may be increased on the first day of each Registrant's fiscal year pursuant to a specified formula.

In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

**PART II** 

**ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE** 

The following documents filed by Registrant with the Commission are incorporated by reference into this Registration Statement:

(a) The Registrant's Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001662774/000119312526151364/qncx-20251231.htm) for the fiscal year ended December 31, 2025, filed with the Commission on April 10, 2026;

(b) The Registrant's Current Reports on Form 8-K filed on [January 29, 2026](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001662774/000119312526029524/d61547d8k.htm) , [February 2, 2026](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001662774/000119312526033758/d52597d8k.htm) , [February 12, 2026](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001662774/000119312526047544/d89820d8k.htm) (excluding Item 2.02), [March 20, 2026](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001662774/000119312526117794/d122428d8k.htm) , [March 30, 2026](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001662774/000119312526130489/d57124d8k.htm) (excluding Item 7.01), and [April 9, 2026](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001662774/000119312526149021/d115661d8k.htm) ; and

(C) The description of the Registrant's Common Stock contained in the registration statement on [Form 8-A](http://www.sec.gov/Archives/edgar/data/1662774/000119312519131785/d739253d8a12b.htm) registering the Registrant's Common Stock under Section 12 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") filed with the Commission on May 1, 2019,
including any amendments or reports filed for purposes of updating such description, including [Exhibit 4.3](http://www.sec.gov/Archives/edgar/data/1662774/000166277425000012/exhibit43-descriptionofsec.htm) to the Registrant's
Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 24, 2025.

All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

------

**Item 8. <u>Exhibits</u>.** 

The following exhibits are filed herewith:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  |  | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
| **Exhibit<br>Number** | **Exhibit Description** | **Form** | **File No.** | **Exhibit** | **Filing Date** | **Filed<br>Herewith** |
| 4.1 | [Specimen Stock Certificate](http://www.sec.gov/Archives/edgar/data/1662774/000119312519123571/d703513dex41.htm) | S-1/A | 333-230853 | 4.1 | 4/29/2019 |  |
| 4.2 | [Description of Securities](http://www.sec.gov/Archives/edgar/data/1662774/000156459020011165/crtx-ex43_369.htm) | 10-K | 001-38890 | 4.3 | 03/16/2020 |  |
| 4.3 | [Form of Pre-Funded Warrant](http://www.sec.gov/Archives/edgar/data/1662774/000119312525140873/d31831dex41.htm) | 8-K | 001-38890 | 4.1 | 6/13/2025 |  |
| 4.4 | [Form of Common Warrant](http://www.sec.gov/Archives/edgar/data/1662774/000119312525140873/d31831dex42.htm) |  | 001-38890 | 4.2 | 6/13/2025 |  |
| 5.1 | [Opinion of Dorsey & Whitney, LLP](d117236dex51.htm) |  |  |  |  | X |
| 23.1 | [Consent of Dorsey & Whitney, LLP (included in Exhibit 5.1)](d117236dex51.htm) |  |  |  |  | X |
| 23.2 | [Consent of Independent Registered Public Accounting Firm](d117236dex232.htm) |  |  |  |  | X |
| 24.1 | [Power of Attorney (included on the signature page of this Registration Statement)](#tx117236_1) |  |  |  |  | X |
| 99.1 | [2019 Equity Incentive Plan, and forms of stock award agreements thereunder](http://www.sec.gov/Archives/edgar/data/1662774/000095017024039440/qncx-ex10_6.htm) | 10-K | 001-38890 | 10.6 | 4/1/2024 |  |
| 99.2 | [2019 Employee Stock Purchase Plan](http://www.sec.gov/Archives/edgar/data/1662774/000119312519123571/d703513dex105.htm) | S-1/A | 333-230853 | 10.5 | 4/29/2019 |  |
| 107 | [Filing Fee Table](d117236dexfilingfees.htm) |  |  |  |  | X |

---

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on April 17, 2026.

---

| |
|:---|
| **QUINCE THERAPEUTICS, INC.** |
| /s/ Dirk Thye |
| **Dirk Thye, M.D.** |
| Chief Executive Officer, Chief Medical<br> Officer and Director |

---

**Power of Attorney** 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Dirk Thye and Brendan Hannah, and each of them, as his or her true and lawful attorney-in-fact and agent with the full power of substitution, for him or her, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments to this Registration Statement on Form S-8), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitutes, may lawfully do or cause to be done by virtue hereof.

------

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated:

---

| | | |
|:---|:---|:---|
| **Name** | **Title** | **Date** |
| /s/ Dirk Thye<br> **Dirk Thye, M.D.** | Chief Executive Officer and Director<br> (*Principal Executive Officer*) | April 17, 2026 |
| /s/ Brendan Hannah<br> **Brendan Hannah** | Chief Business Officer and Chief Operating Officer<br> (*Principal Financial and Accounting Officer*) | April 17, 2026 |
| /s/ David A. Lamond<br> **David A. Lamond** | Director | April 17, 2026 |
| /s/ Christopher J. Senner<br> **Christopher J. Senner** | Director | April 17, 2026 |

---

## Exhibit 5.1

**Exhibit 5.1** 

April 17, 2026

Quince Therapeutics, Inc.

611 Gateway Boulevard, Suite 273

South San Francisco, CA 94080

Re: <u>Registration Statement on Form S-8</u>

Ladies and Gentlemen:

We have acted as counsel to Quince Therapeutics, Inc., a Delaware corporation (the "Company"), in connection with a Registration Statement on Form S-8 (the "Registration Statement") filed by the Company with the Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Securities Act"), relating to up to 268,293 shares of common stock, par value $0.001 per share, of the Company (the "Shares") that may be issued pursuant to (i) the Company's 2019 Equity Incentive Plan (the "2019 EIP") and (ii) the Company's 2019 Employee Stock Purchase Plan (together with the 2019 EIP, the "Plans").

We have examined such documents and have reviewed such questions of law as we have considered necessary or appropriate for the purposes of our opinions set forth below. In rendering our opinions set forth below, we have assumed the authenticity of all documents submitted to us as originals, the genuineness of all signatures and the conformity to authentic originals of all documents submitted to us as copies. We have also assumed the legal capacity for all purposes relevant hereto of all natural persons. As to questions of fact material to our opinions, we have relied upon certificates or comparable documents of officers and other representatives of the Company and of public officials.

Based on the foregoing, we are of the opinion that the Shares, when issued and delivered in accordance with the terms of the Plan, will be validly issued, fully paid and non-assessable.

Our opinions expressed above are limited to the Delaware General Corporation Law.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving this consent, we do not admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder.

Very truly yours,

/s/ Dorsey & Whitney, LLP

DFM/DPL

## Exhibit 23.2

**Exhibit 23.2** 

<u>Consent of Independent Registered Public Accounting Firm</u> 

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated April 10, 2026, relating to the consolidated financial statements of Quince Therapeutics, Inc. (the Company) appearing in the Company's Annual Report on Form 10-K for the year ended December 31, 2025. Our report contains an explanatory paragraph regarding the Company's ability to continue as a going concern.

/s/ BDO USA, P.C.

San Jose, California

April 10, 2026

BDO USA, P.C., a Virginia professional corporation, is the U.S. member of BDO International Limited, a UK company limited by guarantee, and forms part of the international BDO network of independent member firms.

BDO is the brand name for the BDO network and for each of the BDO Member Firms.

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Quince Therapeutics, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, par value $0.001 per share, Quince Therapeutics, Inc. 2019 Equity Incentive Plan | Other | 214635 | $1.185 | $254342.48 | 0.0001381 | $35.12 |
| 2 | Equity | Common Stock, par value $0.001 per share, Quince Therapeutics, Inc. 2019 Employee Stock Purchase Plan | Other | 53658 | $1.01 | $54194.58 | 0.0001381 | $7.49 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $308537.06  |  | $42.61  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $42.61  |

---

 **Offering Note** <br>

<sup>1</sup> (1) Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of common stock, par value $0.001 per share ("Common Stock") of Quince Therapeutics, Inc. (the "Registrant") that become issuable under the 2019 Equity Incentive Plan (the "2019 EIP") or 2019 Employee Stock Purchase Plan (the "2019 ESPP") set forth herein by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of Registrant's Common Stock, as applicable. (2) Estimated in accordance with Rule 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee on the basis of the average of the high and low prices of the Registrant's Common Stock as reported on the Nasdaq Global Select Market on April 15, 2026. (4) Represents 214,635 additional shares of the Registrant's Common Stock that were automatically added to the shares authorized for issuance under the Registrant's 2019 EIP on January 1, 2026, pursuant to an annual "evergreen" increase provision contained in the 2019 EIP.

<sup>2</sup> (1) Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of common stock, par value $0.001 per share ("Common Stock") of Quince Therapeutics, Inc. (the "Registrant") that become issuable under the 2019 Equity Incentive Plan (the "2019 EIP") or 2019 Employee Stock Purchase Plan (the "2019 ESPP") set forth herein by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of Registrant's Common Stock, as applicable. (3) Estimated in accordance with Rule 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee on the basis of the average of the high and low prices of the Registrant's Common Stock as reported on the Nasdaq Global Select Market on April 15, 2026, multiplied by 85%, which is the percentage of the price per share applicable to purchases under the 2019 ESPP. Under the 2019 ESPP, the purchase price of a share of Common Stock is equal to 85% of the fair market value of the Registrant's Common Stock on the offering date or the purchase date, whichever is less. (5) Represents 53,658 additional shares of the Registrant's Common Stock that were automatically added to the shares authorized for issuance under the Registrant's 2019 ESPP on January 1, 2026, pursuant to an annual "evergreen" increase provision contained in the 2019 ESPP.

---

| |
|:---|
| |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---